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Objectives
Current WHO guidelines recommend the treatment of all HIV-infected individuals with
antiretroviral therapy (ART) to improve survival and quality of life, and decrease infection of
others. MaxART is the first implementation trial of this strategy embedded within a government-
managed health system, and assesses mortality as a secondary outcome. Because primary findings
strongly supported scale-up of the ‘treat all’ strategy (hereafter Treat All), this analysis examines
mortality as an additional indicator of its impact.
Methods
MaxART was conducted in 14 Eswatinian health clinics through a clinic-based stepped-wedge
design, by transitioning clinics from then-national standard of care (SoC) to the Treat All
intervention. All-cause, disease-related, and HIV-related mortality were analysed using the Cox
proportional hazards model, censoring SoC participants at clinic transition. Median follow-up time
among study participants was 292 days. There were 36/2034 deaths in SoC (1.77%) and 49/1371
deaths in Treat All (3.57%).
Results
Between September 2014 and August 2017, 3405 participants were enrolled. In SoC and Treat All
interventions, respectively, the multivariable-adjusted 12-month all-cause mortality rates were
1.42% [95% confidence interval (CI): 0.66–2.17] and 1.60% (95% CI: 0.78–2.40), disease-related
mortality rates were 1.02% (95% CI: 0.40–1.64) and 1.10% (95% CI: 0.46–1.73), and HIV-related
mortality rates were 1.03% (95% CI: 0.40–1.65) and 0.99% (95% CI: 0.40–1.58). Treat All had no
impact on all-cause [hazard ratio (HR) = 1.12, 95% CI: 0.58–2.18, P = 0.73], disease-related
(HR = 1.04, 95% CI: 0.52–2.11, P = 0.90), or HIV-related mortality (HR = 0.93, 95% CI: 0.46–1.87,
P = 0.83).
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Conclusion
There was no immediate benefit of the Treat All strategy on mortality, nor evidence of harm.
Longer follow-up of participants is needed to establish long-term consequences.
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Introduction
HIV and AIDS continue to be a major global public
health issue. UNAIDS estimated there were 36.9 million
people living with HIV in 2017 [1]. The vast majority of
HIV infections burdens those located in low- and middle-
income countries, with an estimated 66% of people living
with HIV (PLHIV) residing in sub-Saharan Africa [2].
In 2017, 940 000 people died of AIDS-related illnesses
globally. While this number has significantly reduced
since the peak of 1.9 million in 2004 [2], HIV/AIDS
remains as one of the leading causes of death in sub-
Saharan Africa [3]. Eswatini, in particular, has the highest
HIV prevalence in the world with 26% of adults (aged
15–49 years) living with HIV, and a weighted HIV inci-
dence of 2.4% as of 2011, which is the highest national
rate known [4]. In 2018, 2100 out of 190 000 adults liv-
ing with HIV in Eswatini died as a result of AIDS [5],
translating to approximately 11 deaths per 1000 adults
living with HIV.
HIV-associated morbidity and mortality rates have
reduced significantly globally through the introduction of
antiretroviral therapy (ART), which suppresses viral repli-
cation and increases CD4 count, thereby decreasing
opportunistic infections and malignancies associated with
AIDS [6]. The timing of ART initiation also greatly influ-
ences survival outcomes among PLHIV, as studies have
found that early ART access contributes to better survival
[7,8]. However, methodologically, it would also be impor-
tant to assess the benefits of early ART initiation by dis-
ease stage, as even in the absence of any benefit of early
ART access, patients presenting at an earlier disease stage
will have longer survival.
In 2016, WHO removed the threshold for ART partici-
pation, recommending that ART be initiated in all adults
with HIV, regardless of WHO clinical stage and CD4 cell
count. The goal was to implement a treat all approach
(hereafter Treat All) for immediate ART initiation follow-
ing HIV diagnosis [9]. The MaxART trial was thus imple-
mented to determine the impact of the Treat All strategy
on retention in care and viral suppression compared with
that of the then-national standard of care (SoC) in Eswa-
tini [10]. The trial was conducted in a public health sector
setting and reflected strong support of the scale-up of the
Treat All strategy in Eswatini and countries with similar
HIV epidemics and health systems. However, even though
there were increased retention and viral suppression
results from the Treat All strategy [combined hazard ratio
(HR) = 4.88, 95% confidence interval (CI): 2.96–8.05,
P < 0.001], the relative mortality between SoC and Treat
All participants in MaxART is not known. Moreover, of
the four other community-based universal HIV testing
and treatment trials implemented in sub-Saharan Africa
[ANRS 12249 Treatment as Prevention (TasP) trial in
South Africa, HPTN 071 (PopART) trial in South Africa
and Zambia, BCPP/YaTsie in Botswana, and SEARCH in
Uganda and Kenya], mortality as a secondary outcome
has not yet been examined [11].
As MaxART is the first Treat All implementation trial
embedded within a government-managed health system,
this secondary analysis to MaxART investigates mortality
rates associated with the Treat All strategy as compared
with those with later ART initiation. The results on long-
evity in accordance with this strategy, which has become
more commonly adapted especially in countries with high
prevalence settings such as Eswatini, will serve as an
additional indicator of its impact.
Methods
Trial background
The MaxART trial was conducted in 14 public sector
health clinics in Eswatini. The trial was implemented
using a clinic-based stepped-wedge design. Baseline data
were collected for 4 months in all clinics, and then the
Treat All intervention commenced with one pair of ran-
domly assigned clinics transitioning from Eswatini’s SoC
of ART initiation to the intervention at pre-specified
dates at each 4-month step.
The ART-na€ıve HIV-positive participants, aged 18 years
or older, with no mental illness, and not pregnant or
breastfeeding within 30 days of enrolment were eligible
for the trial. Verbal informed consent was sought from
eligible participants to ensure they were ready to start
ART outside of national guidelines, regardless of whether
the participant was initiated on the control or the inter-
vention phase, and included a description of purpose of
the study, the study procedures, and the anticipated risks
and benefits of providing laboratory samples. An in-
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country Community Advisory Board was established as a
part of this study to ensure that the study was imple-
mented in accordance with community values, culture,
social practices, human rights and ethical standards.
Patients incurred no penalties if they refused to partici-
pate in the study, and continued to receive the standard
of care as described in the national HIV treatment guide-
lines. Those who declined to enrol in the study were still
given the option to receive ART even if their CD4 count
was above the current national HIV treatment guidelines,
but were excluded from study.
In the SoC phase, participants meeting SoC ART eligi-
bility criteria were referred for ART initiation, while those
not eligible were enrolled in pre-ART care. During the
course of the trial, the ongoing changes in the SoC ART
eligibility guidelines were incorporated into the trial
implementation. From 1 September 2014 to 1 December
2015, the ART initiation threshold was a CD4 count of
≤ 350 cells/µL and/or WHO Stage 3 or 4. On 1 December
2015, the threshold changed to a CD4 count of ≤ 500
cells/µL and/or WHO Stage 3 or 4, then on 1 October
2016, Eswatini adopted the Treat All strategy as SoC.
Under Treat All, all HIV participants were eligible for
ART initiation irrespective of their CD4 count or WHO
stage.
The trial started on 1 September 2014. The last pair
was transitioned on 1 October 2016 when Eswatini chan-
ged the SoC from a CD4 count of ≤ 500 cells/µL to the
Treat All strategy. The total duration of the trial was
36 months.
Statistical analysis
Standard operating procedures for data management were
implemented in the 14 clinics to transfer participant
records in the clinics’ usual paper-based files to an elec-
tronic database. Nurse mentors regularly reviewed the
participant files, and provided mentorship to the clinic
staff.
Three mortality endpoints – all-cause, disease-related,
and HIV-related mortality – were analysed to observe the
effect of the Treat All intervention on mortality patterns
among PLHIV. Disease-related mortality refers to deaths
caused by any kind of disease but not accidents, violence,
or injury. HIV-related deaths are a subset of disease-re-
lated deaths plausibly caused by HIV infection. Deaths
were primarily identified by following up with partici-
pants with missed appointments or were lost to follow-
up. In very rare cases, relatives of the participants
reported to the facilities that the participants had died.
Once death has been established, the MaxART team
reached out to the participants’ relatives and collected
data on events prior to the participants’ deaths. This
information was then reviewed by an MD and a decision
was made on the classification of the cause of death.
All analyses described were additionally performed for
two sub-groups. Those with CD4 counts ≥ 350 cells/µL
(or 500 cells/µL after 1 December 2015) and not in WHO
stage 3 or 4, were sub-grouped as ‘SoC-ineligible’ partici-
pants, as they were only eligible for ART under Treat All.
The rest who were eligible for ART under SoC at the time
of their enrolment were thus ‘SoC-eligible’ participants.
Under intent-to-treat analysis, survival curves were
adjusted for step-time by a set of indicator variables, and
the Breslow estimator was used to estimate cumulative
incidence rates. Step-time-adjusted cumulative incidence
rates were calculated at the mean step-time in the popu-
lation follow-up experience, and multivariable-adjusted
cumulative incidence rates were additionally calculated at
the mean level of all covariates included in the Cox pro-
portional hazards model. In addition, SoC participants
were censored at the time of their clinic transition. In the
multivariable-adjusted analyses, a wide range of known
or suspected determinants of mortality were included –
age, sex, marital status, education, CD4 count, WHO
stage, body mass index (BMI), tuberculosis screening, and
viral load at study enrolment, as well as baseline facility
volume, level of facility, days between testing HIV-posi-
tive and study enrolment, and access to HIV treatment
supporter. When the number of cases in a model was lim-
ited, a reduced set of covariates were fitted. A compet-
ing-risks approach was used to estimate disease-related
and HIV-related mortality rates [12]. The missing indica-
tor method was used to handle missing covariate data.
Sensitivity analysis using inverse probability weighting
was additionally performed to assess the potential for
bias due to missing covariate data arising from the use of
the missing covariate indicator method [13].
Each mortality endpoint was analysed using the Cox
proportional hazards model censoring SoC participants at
clinic transition. Because clustered models are numeri-
cally unstable when there is a very small amount of clus-
tering and tend to underestimate the variance, the data
were analysed as non-clustered because the between-fa-
cility intraclass correlations for all endpoints were < 1%
[14]. To assess departure from the proportional hazards
assumption, for each endpoint, a likelihood ratio test
between the multivariate-adjusted model and the same
model additionally containing a time-dependent interac-
tion term between intervention status and time since
enrolment was used.
Effect modification between intervention status and
each of these covariates was evaluated. This analysis was
not conducted for sub-groups with < 20 deaths because
© 2020 British HIV Association HIV Medicine (2020)
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the statistical power was unlikely to be sufficient to
detect the effect modification. Heterogeneity tests were
performed through likelihood ratio tests. All statistical
analyses were performed in SAS version 9.4 (SAS Insti-
tute, Inc., Cary, NC, USA).
Results
MaxART is a stepped-wedge trial, with all clusters being
in both the control and intervention groups, and no clus-
ters were lost to follow-up. Between 1 September 2014
and 31 August 2017, there were 3485 potential partici-
pants in the 14 participating clinics. After further screen-
ing of study eligibility, 80 participants (2%) were
excluded from the trial due to a priori exclusion criteria,
leaving a total of 3405 study participants who were con-
sented and enrolled in the trial (Fig. 1). Of these, 2034
(60%) were enrolled during the SoC phase of their clinics,
and 1371 (40%) were enrolled during the intervention
phase (Fig. 2). In all, 1225 participants were grouped as
‘SoC-ineligible’ participants, while 2180 participants were
‘SoC-eligible’. There were 493 study participants lost to
follow-up, of whom 327 were in SoC and 166 were in
Treat All. After censoring SoC participants at clinic tran-
sition, 48 (15%) SoC participants were censored, leaving
279 participants in the SoC group lost to follow-up. The
median follow-up time among all participants was
292 days.
Figure 2 shows the distribution of enrolment by clinic
and step. In step 1, all pre-ART participants were enrolled
into the trial. However, in later steps, only participants,
including returning pre-ART participants, who were
newly diagnosed or had previously disengaged from pre-
ART were enrolled. As all sites started in the SoC stage,
more participants were enrolled during the SoC phase
than during Treat All.
Table 1 provides basic characteristics of MaxART study
participants at study enrolment. Demographic characteris-
tics did not significantly differ over the study period
except for sex, where 34% and 44% of the participants
enrolled under SoC and Treat All were male, respectively.
However, clinical characteristics did change over time:
44% of participants in SoC, compared with 56% in Treat
All, enrolled with baseline CD4 count < 350 cells/µL.
Additionally, 59% of participants in SoC enrolled within
a year of HIV diagnosis, whereas 79% of participants in
Treat All did so. Even though there was a higher propor-
tion of Treat All participants enrolled within a year of
HIV diagnosis compared with SoC participants, there was
also a higher proportion of Treat All participants with a
Excluded: protocol violations (n = 80) ;
pregnant (n = 23), breastfeeding (n = 6), 
age < 18 (n = 3), not ART-naïve(n = 23), 
HIV-negative (n = 20), psychiatric  
diagnoses (n = 4),HIV-negative and 
psychiatric diagnosis (n = 1)
New & returning pre-ART participants at the 
14 clinics during the study enrollment period
(n = 3485) 
Total MaxART trial participants enrolled (n = 3405)
Enrolled in control phase 
of the stepped-wedge trial
(n = 2034)
Enrolled in intervention 
phase of the stepped- 
wedge trial (n = 1371)
Fig. 1 Flow diagram of participants enrolled during the control [national standard of care (SoC)] and intervention (Treat All) phases in Max-
ART.
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baseline CD4 count < 350 cells/µL. This may have been a
result of randomization, or could have been due to Treat
All being implemented in later calendar times, resulting
in Treat All participants having waited longer to be diag-
nosed after being infected.
Table 2 provides step-time-adjusted mortality rates per
person-year and HRs for all-cause, disease-related and
HIV-related mortality. There were 36/2034 (1.8%) all-
cause deaths in the SoC group over a median follow-up
time of 268.50 years over 1665.65 person-years, and 49/
1371 (3.6%) deaths in the Treat All group over a median
follow-up time of 322.00 years over 1364.58 person-
years. There were 34 and 47 diseases-related deaths, and
32 and 44 HIV-related deaths, in the SoC and Treat All
groups, respectively. The Treat All strategy had no impact
on all-cause mortality (HR = 1.12, 95% CI: 0.58–2.18,
P = 0.73), disease-related mortality (HR = 1.12, 95% CI:
0.57–2.21, P = 0.74), or HIV-related mortality (HR = 0.93,
95% CI: 0.46–1.87, P = 0.83). There were no material dif-
ferences between the multivariable-adjusted HRs which
used the missing covariate indicator method and those
obtained from the sensitivity analysis (missing covariate
indicator method – all-cause mortality, HR = 1.12, 95%
CI: 0.58–2.18, P = 0.73; disease-related mortality, HR =
1.04, 95% CI: 0.52–2.11, P = 0.90; HIV-related mortality,
HR = 0.93, 95% CI: 0.46–1.87, P = 0.83; sensitivity anal-
ysis – all-cause mortality, HR = 1.15, 95% CI: 0.43–3.02,
P = 0.78; disease-related mortality, HR = 0.85, 95% CI:
0.30–2.37, P = 0.75; HIV-related mortality, HR = 1.09,
95% CI: 0.39–3.09, P = 0.87).
Survival curves were compared between the SoC and
Treat All groups. At 1 year, in SoC and Treat All, respec-
tively, the all-cause mortality rates were 1.42% (95% CI:
0.66–2.17) and 1.60% (95% CI: 0.78–2.40) (Fig. 3), the
disease-related mortality rates were 1.18% (95% CI: 0.51–
1.84) and 1.36% (95% CI: 0.62–2.10) (Fig. 4), and the
HIV-related mortality rates were 1.02% (95% CI: 0.40–
1.64) and 1.00% (95% CI: 0.40–1.59) (Fig. 5).
In the SoC-ineligible group, the Treat All strategy had
no impact on all-cause mortality (HR = 1.65, 95% CI:
Steps (4 month periods)
Group Clinic 1 2 3 4‡ 5 6 7§ 8 9 Total
1
1 67 58 34 14 20 20 13 15 4 245
2 81 27 23 10 8 18 13 13 7 200
2
3 27 13 17 6 14 12 13 12 8 122
4 37 12 56 14 19 16 8 5 5 172
3
5 27 13 10 13 14 9 15 5 1 107
6 50 27 33 34 25 23 17 11 6 226
4
7 20 5 6 10 4 8 4 5 14 76
8 163 87 83 116 109 78 43 57 62 798
5
9 93 45 30 17 22 18 6 19 22 272
10 64 28 29 29 18 35 15 16 7 241
6
11 59 23 30 34 30 27 24 21 10 258
12 54 16 34 20 9 26 23 16 13 211
7
13 16 18 18 22 12 7 17 6 4 120
14 112 63 36 27 34 33 24 10 18 357
Total 870 435 439 366 338 330 235 211 181 3405
Fig. 2 Clinic-based step-wedged trial diagram showing number of enrolled participants by clinic pair and steps. Calendar times for each step
are as follows: 1, September 2014–December 2014; 2, January 2015–April 2015; 3, May 2015–August 2015; 4, September 2015–December
2015; 5, January 2016–April 2016; 6, May 2016–August 2016; 7, September 2016; 8, 9, October 2016–August 2017. ‡, Eswatini antiretroviral
therapy (ART) guidelines for ART initiation changed from a CD4 count threshold of ≤ 350 cells/lL to ≤ 500 cells/µL on December 2015. §,
Eswatini’s national ART guidelines for ART initiation changed from a CD4 count threshold of ≤ 500 cells/lL to a universal test and treat
approach on October 2016.
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0.29–9.42, P = 0.57), disease-related mortality (HR =
4.40, 95% CI: 0.55–35.47, P = 0.16), and HIV-related
mortality (HR = 1.77, 95% CI: 0.18–17.57, P = 0.63). In
the SoC-eligible group, the Treat All strategy also did not
influence all-cause mortality (HR = 0.85, 95% CI: 0.44–
1.64, P = 0.62), disease-related mortality (HR = 1.15, 95%
CI: 0.62–2.13, P = 0.65) and HIV-related mortality (HR =
1.17, 95% CI: 0.62–2.20, P = 0.62). As expected, the esti-
mated HRs for the SoC-eligible group were closer to 1,
compared with those from the main analyses and the
SoC-ineligible group because everyone was able to
receive ART at study enrolment in the SoC-eligible group,
resulting in little distinction between SoC and Treat All
participants. No significant effect modification of the
intervention effect by any covariate was observed for any
endpoint (Tables S1–S3). It is likely that these tests were
underpowered because the trial was not designed to
assess effect modification.
Discussion
Since 2002, WHO guidelines on ART access have been
evolving in accordance with growing evidence of the
benefit of earlier initiation of ART, including reduced
mortality, morbidity, and HIV transmission. In 2016, the
WHO strongly recommended that ART should be initiated
in all adults living with HIV, regardless of WHO clinical
stage and CD4 cell count.
The MaxART study is the only trial to study retention
and viral suppression as primary endpoints to assess the
effectiveness of early ART access. The trial found strong
causal evidence that the Treat All strategy increased viral
suppression and retention, and demonstrated that this
strategy can be successfully implemented in a public
Table 1 Basic characteristics of all antiretroviral therapy (ART)-
na€ıve participants at the time of study enrolment
Standard of
care
(n = 2034)
Treat All
(n = 1371)
All ART-na€ıve
(n = 3405)
Demographic characteristics
Age at trial enrolment
(year) median (q1,
q3)
33 (28,42) 33 (27,40) 33 (27,41)
Age group (years) [n (%)]
18 to < 20 40 (2%) 34 (2%) 74 (2%)
20 to < 30 679 (33%) 472 (34%) 1151 (34%)
30 to < 40 722 (35%) 500 (36%) 1222 (36%)
40 to < 50 354 (17%) 230 (17%) 584 (17%)
50 to < 60 156 (8%) 97 (7%) 253 (7%)
60+ 83 (4%) 38 (3%) 121 (4%)
Sex n (%)
Male 695 (34%) 603 (44%) 1298 (38%)
Female 1339 (66%) 768 (56%) 2107 (62%)
Marital status [n (%)]
Married 1045 (52%) 634 (48%) 1679 (51%)
Divorced/widowed 127 (6%) 78 (6%) 205 (6%)
Single 825 (41%) 614 (46%) 1439 (43%)
Marital status missing [n
(%)]
37 (2%) 45 (3%) 82 (2%)
Education, n (%)
Illiterate/primary 589 (40%) 384 (38%) 973 (39%)
Secondary 438 (30%) 362 (36%) 800 (32%)
High school 401 (27%) 218 (22%) 619 (25%)
Tertiary 48 (3%) 37 (4%) 85 (3%)
Education missing [n (%)] 558 (27%) 370 (27%) 928 (27%)
Clinical characteristic†
BMI (kg/m2) [n (%)]
< 18.5 82 (4%) 81 (6%) 163 (5%)
18.5 to < 25 971 (49%) 762 (57%) 1733 (52%)
25 to < 30 529 (27%) 281 (21%) 810 (25%)
≥ 30 387 (20%) 212 (16%) 599 (18%)
BMI missing [n (%)] 65 (3%) 35 (3%) 100 (3%)
CD4 count (cells/µL) [n (%)]
< 350 804 (44%) 632 (56%) 1436 (49%)
350–500 441 (24%) 224 (20%) 665 (22%)
> 500 591 (32%) 266 (24%) 857 (29%)
CD4 missing n (%) 198 (10%) 249 (18%) 447 (13%)
WHO stage [n (%)]
1 1074 (63%) 800 (63%) 1874 (63%)
2 357 (21%) 320 (25%) 677 (23%)
3 or 4 264 (16%) 146 (12%) 410 (14%)
WHO stage missing [n
(%)]
339 (17%) 105 (8%) 444 (13%)
Screened for tuberculosis (TB) symptoms [n (%)]
Positive 190 (10%) 100 (8%) 290 (9%)
Missing screening for
TB symptoms [n (%)]
82 (4%) 66 (5%) 148 (4%)
Viral load (copies/mL) [n (%)]
< 1000 229 (12%) 120 (10%) 349 (11%)
1000 to < 50 000 781 (41%) 479 (40%) 1260 (41%)
50 000 to
< 100 000
213 (11%) 150 (13%) 363 (12%)
≥ 100 000 661 (35%) 438 (37%) 1099 (36%)
Viral load missing [n
(%)]
150 (7%) 184 (13%) 334 (10%)
Time between testing HIV-positive to trial enrolment (years) [n (%)]
≤ 1 1189 (59%) 1076 (79%) 2265 (67%)
1 to ≤ 3 421 (21%) 134 (10%) 555 (16%)
> 3 413 (20%) 144 (11%) 557 (16%)
Table 1 (Continued)
Standard of
care
(n = 2034)
Treat All
(n = 1371)
All ART-na€ıve
(n = 3405)
Access to HIV treatment supporter [n (%)]
Yes 1980 (97%) 1339 (98%) 3319 (97%)
Clinic characteristics
Level of clinic [n (%)]
Hospital 449 (22%) 349 (25%) 798 (23%)
Clinic with maternity
ward
317 (16%) 181 (13%) 498 (15%)
Clinic without
maternity ward
1268 (62%) 841 (61%) 2109 (62%)
Clinic volume by ART visits at baseline‡[n (%)]
< Median (400 visits) 915 (45%) 385 (28%) 1300 (38%)
≥ Median (400 visits) 1119 (55%) 986 (72%) 2105 (62%)
†
Values within 90 days of enrolment and before ART initiation.
‡
ART participant visits received during the first quarter into trial. Median
number of visits during this period is 400.
© 2020 British HIV Association HIV Medicine (2020)
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sector health system, in particular, in sub-Saharan Afri-
can countries with a high prevalence of HIV [15]. These
primary findings are consistent with those obtained in
the CASCADE trial implemented in Lesotho, which com-
pared same-day home-based ART initiation with usual
care, and found a significant increase in linkage to care
at 3 months and in viral suppression at 12 months [16].
Although the primary analysis strongly supported the
scaling-up of the Treat All strategy, this secondary mor-
tality analysis is inconclusive about the impact of the
strategy on longevity among PLHIV. The mortality rates
under the Treat All strategy were not significantly lower
compared with SoC, as had been hypothesized, whether
for all ART-na€ıve participants, SoC-eligible participants,
(a) (b)
(c)
Fig. 3 Kaplan–Meier curves for all-cause mortality by treatment group. (a) All antiretroviral therapy (ART)-na€ıve participants; (b) national stan-
dard of care (SoC)-ineligible participants; (c) SoC-eligible participants. Mortality rates are evaluated by censoring SoC participants at clinic tran-
sition. Graphs reflect the cumulative incidence averaged over covariates. Time reflects years since study enrolment. (a) Adjusted for step-time,
age at study enrolment (18 to < 20, 20 to < 30, 30 to < 40, 40 to < 50, 50 to < 60, 60+ years), sex, marital status (married, divorced/wid-
owed, single), education (illiterate/primary, secondary, high school, tertiary), CD4 counts at study enrolment (< 350, 350–500, > 500 cells/µL),
WHO stage at study enrolment (stage 1, stage 2, stage 3 or 4), body mass index (BMI) at study enrolment (< 18.5, 18.5 to < 25, 25 to < 30,
≥ 30 kg/m2), tuberculosis (TB) screening positive at study enrolment (yes/no), viral load at study enrolment (< 5000, 5000–30 000, > 30 000
HIV-1 RNA copies/mL), treatment support (yes/no), level of facility (hospital, clinic with maternity, clinic without maternity), time from testing
HIV-positive to enrolment (≤ 1, 1 to ≤ 3, > 3 years), facility volume at study enrolment (low, < median; high, ≥ median). Missing data were
treated as a separate group for each of the covariates in the models. (b) Adjusted for step-time, sex, CD4 counts at study enrolment (< 350,
350–500, > 500 cells/µL), BMI at study enrolment (< 18.5, 18.5 to < 25, 25 to < 30, ≥ 30 kg/m2), viral load at study enrolment (< 5000,
5000–30 000, > 30 000 copies/mL). Due to the small number of events, only limited covariates can be fitted. Missing data were treated as a
separate group for each of the covariates in the models. (c) Adjusted for step-time, age at study enrolment (18–24, 25–39, ≥ 40 years), sex,
marital status (married, divorced/widowed, single), WHO stage at 180 days post-ART initiation (stage 1, stage 2, stage 3 or 4), BMI at study
enrolment (< 25, ≥ 25 kg/m2), TB screening positive at study enrolment (yes/no), viral load at study enrolment (< 5000, 5000–30 000,
> 30 000 copies/mL), level of facility (hospital, clinic with maternity, clinic without maternity), study enrolment date [2 knots stepwise
restricted cubic splines (SRCS)]. Missing data were treated as a separate group for each of the covariates in the models.
© 2020 British HIV Association HIV Medicine (2020)
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or SoC-ineligible participants. Larger studies with longer
durations will be needed to ascertain whether this obser-
vation is spurious or indicative of a causal effect.
There were several limitations to this study. As the
Eswatini national ART guidelines continued to evolve
during the trial, the SoC offered in the trial was conse-
quently required to provide the level of access to ART
specified in the national guidelines. These changes
resulted in SoC treatment increasingly resembling the
Treat All strategy over time, and thereby reducing the
statistical power to detect any impact of the intervention
on mortality rates. Also, while in later steps of the trial,
patients who had previously been disengaged from pre-
ART were enrolled, these participants could not be
(a) (b)
(c)
Fig. 4 Kaplan-Meier curves for disease-related mortality by treatment group. (a) All antiretroviral therapy (ART)-na€ıve participants; (b) national
standard of care (SoC)-ineligible participants; (c) SoC-eligible participants. Mortality rates are evaluated by censoring SoC participants at clinic
transition. Graphs reflect the cumulative incidence averaged over covariates under a competing-risks approach. Time reflects years since study
enrolment. (a) Adjusted for step-time, age at study enrolment (18 to < 20, 20 to < 30, 30 to < 40, 40 to < 50, 50 to < 60, 60+ years), sex,
marital status (married, divorced/widowed, single), education (illiterate/primary, secondary, high school, tertiary), CD4 counts at study enrolment
(< 350, 350–500, > 500 cells/µL), WHO stage at study enrolment (stage 1, stage 2, stage 3 or 4), body mass index (BMI) at study enrolment
(< 18.5, 18.5 to < 25, 25 to < 30, ≥ 30 kg/m2), tuberculosis (TB) screening positive at study enrolment (yes/no), viral load at study enrolment
(< 5000, 5000–30 000, > 30 000 HIV-1 RNA copies/mL), treatment support (yes/no), level of facility (hospital, clinic with maternity, clinic
without maternity), time from testing HIV-positive to enrolment (≤ 1, 1 to ≤ 3, > 3 years), facility volume at study enrolment (low, < median;
high, ≥ median). Missing data were treated as a separate group for each of the covariates in the models. (b) Adjusted for step-time, sex, BMI
at study enrolment (< 18.5, 18.5 to < 25, 25 to < 30, ≥ 30 kg/m2), viral load at study enrolment (< 5000, 5000–30 000, > 30 000 copies/mL).
Due to the small number of events, only limited covariates can be fit. Missing data were treated as a separate group for each of the covariates
in the models. (c) Adjusted for step-time, age at study enrolment (18 to < 20, 20 to < 30, 30 to < 40, 40 to < 50, 50 to < 60, 60+ years),
sex, marital status (married, divorced/widowed, single), WHO stage at 180 days post-ART initiation (stage 1, stage 2, stage 3 or 4), BMI at
study enrolment (< 18.5, 18.5 to < 25, 25 to < 30, ≥ 30 kg/m2), TB screening positive at study enrolment (yes/no), viral load at study enrol-
ment (< 5000, 5000–30 000, > 30 000 copies/mL), level of facility (hospital, clinic with maternity, clinic without maternity). Missing data were
treated as a separate group for each of the covariates in the models.
© 2020 British HIV Association HIV Medicine (2020)
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identified as such, although it is possible that they may
have had different outcomes from the rest of the study
population.
With 36 deaths among 2034 in the SoC group (1.8%)
and 49 deaths among 1371 in the intervention group
(3.6%), there was limited statistical power to detect differ-
ences between the two groups and even less so for modi-
fication of intervention effects by baseline covariates. In
comparison with the same study population from the pri-
mary MaxART analysis, 1311 participants in the SoC
group (64.5%) and 855 in the Treat All group (62.4%)
experienced the combined endpoint of retention and viral
suppression, allowing for substantial power. The median
follow-up time among all participants was also just
292 days, which may not have been a long enough fol-
low-up period to observe mortality patterns. Although a
(a)
(c)
(b)
Fig. 5 Kaplan–Meier curves for HIV-related mortality by treatment group. (a) All antiretroviral therapy (ART)-na€ıve participants; (b) national
standard of care (SoC)-ineligible participants; (c) SoC-eligible participants. Mortality rates are evaluated by censoring SoC participants at clinic
transition. Graphs reflect the cumulative incidence averaged over covariates under a competing-risks approach. Time reflects years since study
enrolment. (a) Adjusted for step-time, age at study enrolment (18 to < 20, 20 to < 30, 30 to < 40, 40 to < 50, 50 to < 60, 60+ years), sex,
marital status (married, divorced/widowed, single), education (illiterate/primary, secondary, high school, tertiary), CD4 counts at study enrolment
(< 350, 350–500, > 500 cells/µL), WHO stage at study enrolment (stage 1, stage 2, stage 3 or 4), body mass index (BMI) at study enrolment
(< 18.5, 18.5 to < 25, 25 to < 30, ≥ 30 kg/m2), tuberculosis (TB) screening positive at study enrolment (yes/no), viral load at study enrolment
(< 5000, 5000–30 000, > 30 000 HIV-1 RNA copies/mL), treatment support (yes/no), level of facility (hospital, clinic with maternity, clinic
without maternity), time from testing HIV-positive to enrolment (≤ 1, 1 to ≤ 3, > 3 years), facility volume at study enrolment (low, < median;
high, ≥ median). Missing data were treated as a separate group for each of the covariates in the models. (b) Adjusted for step-time, sex, BMI
at study enrolment (< 18.5, 18.5 to < 25, 25 to < 30, ≥ 30 kg/m2). Due to the small number of events, only limited covariates can be fit.
Missing data were treated as a separate group for each of the covariates in the models. (c) Adjusted for step-time, age at study enrolment (18
to < 20, 20 to < 30, 30 to < 40, 40 to < 50, 50 to < 60, 60+ years), sex, marital status (married, divorced/widowed, single), WHO stage at
180 days post-ART initiation (stage 1, stage 2, stage 3 or 4), BMI at study enrolment (< 18.5, 18.5 to < 25, 25 to < 30, ≥ 30 kg/m2), TB
screening positive at study enrolment (yes/no), viral load at study enrolment (< 5000, 5000–30 000, > 30 000 copies/mL), level of facility (hos-
pital, clinic with maternity, clinic without maternity). Missing data were treated as a separate group for each of the covariates in the models.
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study conducted in China only followed patients for a
maximum of 12 months, and the mortality rates per 100
person-years between the immediate and delayed ART
initiation groups (1.04 and 2.25, respectively) were not
drastically different, the study enrolled nearly 35,000
patients, allowing small differences to reach statistical
significance [8]. While another study done in Lesotho
also found that early ART initiation significantly reduced
mortality, ‘late initiation’ was defined as initiating ART at
CD4 count < 200 cells/µL [17]. Those with such low
baseline CD4 count would probably have had a much
greater risk of death regardless of ART treatment status.
The START trial has also found significant benefits in
immediate ART initiation at a CD4 count> 500 cells/µL
compared with deferring until a CD4 count < 350 cell/µL
in terms of a primary composite endpoint of any serious
AIDS-related or non-AIDS-related event, including mor-
tality [18]. However, it is difficult to assess whether mor-
tality significantly decreased with early ART initiation
from a composite endpoint.
Among all of this study’s limitations, perhaps the most
important is the insufficient follow-up time. A study that
assessed mortality by CD4 count at ART initiation fol-
lowed patients for up to 15 years to assess long-term sur-
vival, and found little evidence that baseline CD4 count
was prognostic for mortality after 5 years of ART, as the
mortality of patients who started ART with low baseline
CD4 count (< 50 cells/µL) converged to that of patients
with intermediate (200–349 cells/µL) to high (≥ 500 cells/
µL) baseline CD4 count [19]. This suggests that differenti-
ation of mortality rates between SoC and Treat All groups
may require at least 5 years of follow-up.
An explanation of such a finding might be due to an
initial adverse effect that crosses over to a longer-term
benefit among the survivors. Some patients starting ART
experience clinical worsening by immune reconstitution
inflammatory syndrome, which in HIV is strongly associ-
ated with pre-existing clinical or subclinical opportunistic
infections or diseases and severe immunodeficiency man-
ifested by low CD4 counts [20]. Some patients on ART
also fail to experience immune reconstitution despite
viral suppression, putting them at higher risk for clinical
events, including death. It is estimated that 50% of ART-
treated patients may fail to reconstitute their CD4 counts
to levels above 500 cells/lL, and up to 16% may not
achieve a CD4 count > 200 cells/ll, even with long-term
therapy. Therefore, longer follow-up of these participants
will be necessary to establish long-term consequences of
the Treat All strategy.
In summary, while the primary study found strong
causal evidence of beneficial effects of the Treat All strat-
egy on retention and viral suppression, supporting the
benefit of scaling-up in Eswatini and other health sys-
tems with similar HIV epidemics, effects on mortality did
not serve as an indicator of its success. However, as a
major purpose of the Treat All strategy is to decrease
infectiousness so that there are no new cases, it is also an
important finding that there is no evidence of harm.
Longer follow-up of these participants will be necessary
to establish long-term consequences, particularly mortal-
ity, of the Treat All protocol.
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